Zhu Yeyi, Hedderson Monique M, Quesenberry Charles P, Feng Juanran, Ferrara Assiamira
Women and Children's Health Section, Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Biostatistics Core, Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Front Endocrinol (Lausanne). 2018 Oct 2;9:581. doi: 10.3389/fendo.2018.00581. eCollection 2018.
Liver enzymes may be implicated in glucose homeostasis; liver enzymes progressively change during pregnancy but longitudinal data during pregnancy in relation to insulin resistance and gestational diabetes (GDM) risk are lacking. We investigated longitudinal associations of γ-glutamyl transferase (GGT) and alanine aminotransferase (ALT) with insulin secretion and resistance markers across early to mid-pregnancy and subsequent GDM risk. Within the prospective Pregnancy Environment and Lifestyle Study cohort, 117 GDM cases were ascertained and matched to 232 non-GDM controls in a nested case-control study. Fasting blood samples were collected at two clinic visits (CV1, gestational weeks 10-13; CV2, gestational weeks 16-19). Linear mixed model and conditional logistic regression were used, adjusting for major risk factors for GDM. In repeated measure analysis, after adjusting for confounders including body mass index and waist-to-hip ratio, GGT per standard deviation increment was associated with elevated fasting glucose and HOMA-IR (% change = 1.51%, 95% CI 0.56-2.46% and 7.43%, 95% CI 1.76-13.11%, respectively) and decreased adiponectin (% change = -2.86%, 95% CI-5.53 to -0.20%) from CV1 to CV2. At CV1 and CV2, GGT levels comparing the highest versus lowest quartile were associated with 3.01-fold (95% CI 1.32-6.85) and 3.51-fold (95% CI 1.37-8.97) increased risk of GDM, respectively. Progressively increased (<median at CV1, ≥median at CV2) and stably high (≥median at both CV1 and CV2) GGT levels were associated with 3.89- and 2.39-fold increased risk of GDM, compared to stably low levels (<median at both CV1 and CV2), respectively (both < 0.05). Similar but non-significant trends were observed for ALT. Elevated levels of GGT in early and mid-pregnancy, even within the conventional normal range, and its progressive increase from early to mid-pregnancy may be implicated in the pathogenesis of GDM, highlighting its potential to inform early screening or preventive strategies to mitigate subsequent risk of GDM.
肝脏酶可能与葡萄糖稳态有关;肝脏酶在孕期会逐渐变化,但缺乏孕期与胰岛素抵抗及妊娠期糖尿病(GDM)风险相关的纵向数据。我们研究了γ-谷氨酰转移酶(GGT)和丙氨酸氨基转移酶(ALT)在妊娠早期至中期与胰岛素分泌及抵抗标志物的纵向关联,以及随后发生GDM的风险。在前瞻性妊娠环境与生活方式研究队列中,在一项巢式病例对照研究中确定了117例GDM病例,并与232例非GDM对照进行匹配。在两次临床就诊时(CV1,孕10 - 13周;CV2,孕16 - 19周)采集空腹血样。使用线性混合模型和条件逻辑回归,并对GDM的主要风险因素进行校正。在重复测量分析中,校正包括体重指数和腰臀比在内的混杂因素后,GGT每增加一个标准差,与空腹血糖升高和胰岛素抵抗指数(HOMA-IR)升高(变化百分比分别为1.51%,95%可信区间0.56 - 2.46%和7.43%,95%可信区间1.76 - 13.11%)以及从CV1到CV2脂联素降低(变化百分比 = -2.86%,95%可信区间 -5.53至 -0.20%)相关。在CV1和CV2时,比较最高四分位数与最低四分位数的GGT水平分别与GDM风险增加3.01倍(95%可信区间1.32 - 6.85)和3.51倍(95%可信区间1.37 - 8.97)相关。与始终较低水平(在CV1和CV2时均<中位数)相比,GGT水平逐渐升高(在CV1时<中位数,在CV2时≥中位数)和始终较高(在CV1和CV2时均≥中位数)分别与GDM风险增加3.89倍和2.39倍相关(均P<0.05)。ALT观察到类似但无统计学意义的趋势。妊娠早期和中期GGT水平升高,即使在传统正常范围内,以及从妊娠早期到中期的逐渐升高可能与GDM的发病机制有关,突出了其为早期筛查或预防策略提供信息以降低后续GDM风险的潜力。